Results 111 to 120 of about 1,677 (149)

外源性SHIP基因表达抑制生长因子介导的 K562细胞增殖及Akt磷酸化

Zhongshan Daxue xuebao. Yixue kexue ban, 2009
【目的】 探讨SHIP基因对IL-3诱导K562细胞系增殖的抑制作用,阐明SHIP对K562细胞作用的机制65377;【方法】 将慢病毒质粒pReceiver-Lv31-FIV和pReceiver-Lv31-SHIP转染K562细胞;转染细胞与IL-3共培养,Western blot法检测K562细胞Akt磷酸化;观察转染野生型SHIP基因对K562细胞增殖的影响;末端脱氧核苷酸转移酶介导的dUTP缺失末端标记(TUNEL)法检测细胞凋亡65377;【结果】 重组慢病毒载体pReceiver-Lv31 ...
doaj  

[Recent advances in antibody-drug conjugates for metastatic castration-resistant prostate cancer]. [PDF]

Zhejiang Da Xue Xue Bao Yi Xue Ban
Xu J, Ma Y, Hu P, Yao J, Chen H, Ma Q.
europepmc   +1 more source

["Chongqing experiences" in treatment of bone infections]. [PDF]

Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
Xie Z.
europepmc   +1 more source

[Role of <i>Brg1</i> in regulating the Wnt/β-catenin signaling pathway in a bronchopulmonary dysplasia model]. [PDF]

Zhongguo Dang Dai Er Ke Za Zhi
Guan L, Xu MZ, Ling YZ, Yang LL, Zhang LH, Liu S, Zou WJ, Fu Z.   +7 more
europepmc   +1 more source

[Protective effect of knock-down the expression of <i>Blimp1</i> gene on early liver injury in CCl₄-induced mouse model of liver fibrosis]. [PDF]

Beijing Da Xue Xue Bao Yi Xue Ban
Qin Q, Li R, Zhou Y, Zhang Y, Han M, Zhu L.   +5 more
europepmc   +1 more source

[Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Xuan L, Huang H, Xu LP, Fu YW, Chen F, Wang Y, Wang SQ, Dong L, Wu JY, Wu DP.   +9 more
europepmc   +1 more source

Role of miRNAs in Lung Cancer [PDF]

, 2009
William CS CHO
core  

[PINK1 suppresses colorectal cancer cell growth through epigenetic regulation of histone modifications]. [PDF]

Zhejiang Da Xue Xue Bao Yi Xue Ban
Wang M, Luan S, Fan X, Han D, Zhu Y.
europepmc   +1 more source

[Angio-associated migratory cell protein is highly expressed in hepatocellular carcinoma and promotes tumor cell invasion and metastasis]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Li C, Yin G, Cheng X, Jiang Y.
europepmc   +1 more source

[Advances in the application strategies of CRISPR/Cas9 technology in chimeric antigen receptor T cell therapy for hematological malignancies]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Wang YW, Tang YM.
europepmc   +1 more source